The Effect of Radioiodine Treatment on the Characteristics of TRAb in Graves' Disease

Overview

Journal BMC Endocr Disord

Publisher Biomed Central

Specialty Endocrinology

Date 2021 Dec 1

PMID 34847904

Citations 4

Authors

Ya Fang

Wen-Hua Du

Cao-Xu Zhang

Shuang-Xia Zhao

Huai-Dong Song

Guan-Qi Gao

Mei Dong

Affiliations

Soon will be listed here.

Abstract

Background: Graves' disease (GD) is one of the most common autoimmune thyroid diseases (AITDs) in humans, and thyrotropin receptor antibody (TRAb) is a characterized autoantibody in GD. The use of radioactive iodine therapy (RAI) for GD treatment is increasing.

Objectives: We studied the biological properties of TRAb and evaluated the effect of RAI therapy on TRAb in GD patients.

Methods: In total, 225 patients (22 onset GD patients without I therapy, 203 GD patients treated with I therapy) and 20 healthy individuals as normal controls were included in this study. Clinical assessments were performed, and we examined in vitro the biological properties of TRAb in the 22 onset GD patients and 20 controls as well as 84 GD patients with I therapy.

Results: Serum TRAb and thyroid peroxidase antibody (TPOAb) levels increased in the initial year of RAI treatment, and both antibodies decreased gradually after one year. After 5 years from radioiodine treatment, TRAb and TPOAb levels decreased in 88% and 65% of GD patients, respectively. The proportion of patients positive for thyroid-stimulatory antibody (TSAb) was significantly higher in the 7-12-month group, and thyroid-blocking antibody (TBAb) levels were elevated after one year in half of the patients who received I treatment.

Conclusions: Treatment of GD patients with radioiodine increased TPOAb and TRAb (their main biological properties were TSAbs) within the first year after therapy, and the main biological properties of elevated TRAb were TBAbs after 1 year.

Citing Articles

Predictive Performance of 2 Immunoassays in Patients with Graves Disease Undergoing Radioiodine Therapy: Prospective Study.

de Souza M, Sapienza M, Brito L, Cortez P, Marui S J Endocr Soc. 2025; 9(3):bvaf016.

PMID: 39935695 PMC: 11811413. DOI: 10.1210/jendso/bvaf016.

Coexistence of Hashimoto's Thyroiditis in Differentiated Thyroid Cancer: Post-Operative Monitoring of Anti-Thyroglobulin Antibodies and Assessment of Treatment Response.

Donnici A, Mirabelli M, Giuliano S, Misiti R, Tocci V, Greco M Diagnostics (Basel). 2024; 14(2).

PMID: 38248043 PMC: 10814696. DOI: 10.3390/diagnostics14020166.

A Review of Testing for Distinguishing Hashimoto's Thyroiditis in the Hyperthyroid Stage and Grave's Disease.

Liu Y, Liu X, Wu N Int J Gen Med. 2023; 16:2355-2363.

PMID: 37313042 PMC: 10259585. DOI: 10.2147/IJGM.S410640.

Effect of liver dysfunction on outcome of radioactive iodine therapy for Graves' disease.

Ze Y, Shao F, Feng X, Shen S, Bi Y, Zhu D BMC Endocr Disord. 2022; 22(1):319.

PMID: 36522617 PMC: 9753361. DOI: 10.1186/s12902-022-01242-w.

[Value of thyroid TcO imaging ROI ratio for estimating I dose in individualized treatment of hyperthyroidism].

Qi Y, Chi X, Jiang Y, Huang K, Liu F, Liu Z Nan Fang Yi Ke Da Xue Xue Bao. 2022; 42(11):1618-1627.

PMID: 36504054 PMC: 9742783. DOI: 10.12122/j.issn.1673-4254.2022.11.05.

References

Carella C, Mazziotti G, Sorvillo F, Piscopo M, Cioffi M, PILLA P . Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify.... Thyroid. 2006; 16(3):295-302. DOI: 10.1089/thy.2006.16.295. View

Liu W, Zhang Q, Yuan F, Wang H, Zhang L, Ma Y . A dense mapping study of six European AITD susceptibility regions in a large Chinese Han Cohort of Graves' disease. Clin Endocrinol (Oxf). 2018; 89(6):840-848. DOI: 10.1111/cen.13847. View

Takasu N, Yamada T, Takasu M, Komiya I, Nagasawa Y, Asawa T . Disappearance of thyrotropin-blocking antibodies and spontaneous recovery from hypothyroidism in autoimmune thyroiditis. N Engl J Med. 1992; 326(8):513-8. DOI: 10.1056/NEJM199202203260803. View

Grulet H, Barraud S, Chikh K, Souchon P, Claris O, Bouvier R . Three Consecutive Pregnancies in a Patient with Chronic Autoimmune Thyroid Disease Associated with Hypothyroidism and Extremely High Levels of Anti-Thyrotropin Receptor Antibodies. Thyroid. 2019; 29(5):743-747. DOI: 10.1089/thy.2018.0098. View

Zhao S, Xue L, Liu W, Gu Z, Pan C, Yang S . Robust evidence for five new Graves' disease risk loci from a staged genome-wide association analysis. Hum Mol Genet. 2013; 22(16):3347-62. DOI: 10.1093/hmg/ddt183. View

Chiovato L, Fiore E, Vitti P, Rocchi R, Rago T, Dokic D . Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab. 1998; 83(1):40-6. DOI: 10.1210/jcem.83.1.4492. View

Aizawa Y, Yoshida K, Kaise N, Fukazawa H, Kiso Y, Sayama N . The development of transient hypothyroidism after iodine-131 treatment in hyperthyroid patients with Graves' disease: prevalence, mechanism and prognosis. Clin Endocrinol (Oxf). 1997; 46(1):1-5. DOI: 10.1046/j.1365-2265.1997.d01-1737.x. View

Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Torring O . TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol. 2008; 158(1):69-75. DOI: 10.1530/EJE-07-0450. View

Tomari S, Watanabe M, Inoue N, Mizuma T, Yamanaka C, Hidaka Y . The polymorphisms in the thyroid peroxidase gene were associated with the development of autoimmune thyroid disease and the serum levels of anti-thyroid peroxidase antibody. Endocr J. 2017; 64(10):1025-1032. DOI: 10.1507/endocrj.EJ17-0191. View

10.

Zhang Q, Liu W, Li L, Du W, Zuo C, Ye X . Genetic Study in a Large Cohort Supported Different Pathogenesis of Graves' Disease and Hashimoto's Hypothyroidism. J Clin Endocrinol Metab. 2020; 105(7). DOI: 10.1210/clinem/dgaa170. View

11.

Gonzalez-Aguilera B, Betea D, Lutteri L, Cavalier E, Geenen V, Beckers A . Conversion to Graves disease from Hashimoto thyroiditis: a study of 24 patients. Arch Endocrinol Metab. 2019; 62(6):609-614. PMC: 10118676. DOI: 10.20945/2359-3997000000086. View

12.

Roggenbuck J, Veiczi M, Conrad K, Schierack P, Wunderlich G, Kotzerke J . A novel third-generation TSH receptor antibody (TRAb) enzyme-linked immunosorbent assay based on a murine monoclonal TSH receptor-binding antibody. Immunol Res. 2019; 66(6):768-776. DOI: 10.1007/s12026-018-9062-z. View

13.

Davies T, Ando T, Lin R, Tomer Y, Latif R . Thyrotropin receptor-associated diseases: from adenomata to Graves disease. J Clin Invest. 2005; 115(8):1972-83. PMC: 1180562. DOI: 10.1172/JCI26031. View

14.

Codaccioni J, Orgiazzi J, Blanc P, Pugeat M, Roulier R, Carayon P . Lasting remissions in patients treated for Graves' hyperthyroidism with propranolol alone: a pattern of spontaneous evolution of the disease. J Clin Endocrinol Metab. 1988; 67(4):656-62. DOI: 10.1210/jcem-67-4-656. View

15.

Mizuma T, Watanabe M, Inoue N, Arakawa Y, Tomari S, Hidaka Y . Association of the polymorphisms in the gene encoding thyroglobulin with the development and prognosis of autoimmune thyroid disease. Autoimmunity. 2017; 50(6):386-392. DOI: 10.1080/08916934.2017.1344971. View

16.

Takasu N, Yoshimura Noh J . Hashimoto's thyroiditis: TGAb, TPOAb, TRAb and recovery from hypothyroidism. Expert Rev Clin Immunol. 2010; 4(2):221-37. DOI: 10.1586/1744666X.4.2.221. View

17.

Husseni M . The Incidence of Hypothyroidism Following the Radioactive Iodine Treatment of Graves' Disease and the Predictive Factors Influencing its Development. World J Nucl Med. 2016; 15(1):30-7. PMC: 4729012. DOI: 10.4103/1450-1147.167582. View

18.

Zophel K, Roggenbuck D, Schott M . Clinical review about TRAb assay's history. Autoimmun Rev. 2010; 9(10):695-700. DOI: 10.1016/j.autrev.2010.05.021. View

19.

Fang Y, Sun F, Zhang R, Zhang C, Yan C, Zhou Z . Mutation screening of the TSHR gene in 220 Chinese patients with congenital hypothyroidism. Clin Chim Acta. 2019; 497:147-152. DOI: 10.1016/j.cca.2019.07.031. View

20.

McKenzie J, Zakarija M . Fetal and neonatal hyperthyroidism and hypothyroidism due to maternal TSH receptor antibodies. Thyroid. 1992; 2(2):155-9. DOI: 10.1089/thy.1992.2.155. View